Clinical Trial of Alpelisib and Tucatinib in Patients with PIK3CA-Mutant HER2-Positive Metastatic Breast Cancer

被引：0
|
作者：
Shagisultanova, Elena
Wisinski, Kari B.
Gawryletz, Chelsea D.
Datko, Farrah M.
Medgyesy, Diana
Diamond, Jennifer R.
Borges, Virginia F.
Kabos, Peter
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT3-09-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-09-01
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Updates in HER2-Positive Metastatic Breast Cancer
    Gadi, V. K.
    Iyengar, Neil
    Isaacs, Claudine
    Kaklamani, Virginia
    ONCOLOGY-NEW YORK, 2021, 35 (09): : 588 - 591
  • [42] Margetuximab in HER2-positive metastatic breast cancer
    Gradishar, William J.
    O'Regan, Ruth
    Rimawi, Mothaffar F.
    Nordstrom, Jeffrey L.
    Rosales, Minori K.
    Rugo, Hope S.
    FUTURE ONCOLOGY, 2023, 19 (16) : 1099 - 1112
  • [43] Therapy for HER2-Positive Metastatic Breast Cancer
    Dekker, Tim J. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25):
  • [44] Alpelisib in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2+, PIK3CA-mutant advanced breast cancer: EPIK-B2 Study Part 1 safety and efficacy results
    Hurvitz, Sara A.
    Bidard, Francois-Clement
    Li, Wei
    Hu, Xichun
    Pernas, Sonia
    Beck, Joseph Thaddeus
    Campone, Mario
    Punie, Kevin
    Miller, Michelle
    Kaper, Mathilde
    Han, Yu
    Ghaznawi, Farhat
    Jerusalem, Guy
    CANCER RESEARCH, 2023, 83 (07)
  • [45] Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer (vol 12, pg 289, 2019)
    Murthy, Rashmi K.
    Loi, Sherene
    Okines, Alicia
    Paplomata, Elisavet
    Hamilton, Erika
    Hurvitz, Sara A.
    Lin, Nancy U.
    Borges, Virginia
    Abramson, Vandana
    Anders, Carey
    Bedard, Philippe L.
    Oliveira, Mafalda
    Jakobsen, Erik
    Bachelot, Thomas
    Shachar, Shlomit S.
    Mueller, Volkmar
    Braga, Sofia
    Duhoux, Francois P.
    Greil, Richard
    Cameron, David
    Carey, Lisa A.
    Curigliano, Giuseppe
    Gelmon, Karen
    Hortobagyi, Gabriel
    Krop, Ian
    Loibl, Sibylle
    Pegram, Mark
    Slamon, Dennis
    Palanca-Wessels, M. Corinna
    Walker, Luke
    Feng, Wentao
    Winer, Eric P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (06): : 586 - 586
  • [46] A phase I clinical trial of entinostat and lapatinib in patients with trastuzumab refractory HER2-positive metastatic breast cancer
    Willey, Jie
    Alvarez, Ricardo H.
    Booser, Daniel J.
    Giordano, Sharon H.
    Gonzalez-Angulo, Ana M.
    Murray, James L.
    Valero, Vincente
    Lee, Jangsoon
    Ueno, Naoto T.
    Jackson, Summer A.
    Faruqi, Fahad A.
    CANCER RESEARCH, 2015, 75
  • [47] Clinical implication of mutation load in patients with HER2-positive refractory metastatic breast cancer
    Park, Yeon Hee
    Park, Kyunghee
    Park, Song Ee
    Lee, Eunjin
    Kim, Ji-Yeon
    Ahn, Jin Seok
    Im, Young-Hyuck
    Jung, Hun
    Lee, Chooghoon
    Park, Woong-Yang
    Cristescu, Razvan
    CANCER RESEARCH, 2018, 78 (13)
  • [48] FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer
    Narayan, Preeti
    Prowell, Tatiana M.
    Gao, Jennifer J.
    Fernandes, Laura L.
    Li, Emily
    Jiang, Xiling
    Qiu, Junshan
    Fan, Jianghong
    Song, Pengfei
    Yu, Jingyu
    Zhang, Xinyuan
    King-Kallimanis, Bellinda L.
    Chen, Wei
    Ricks, Tiffany K.
    Gong, Yutao
    Wang, Xing
    Windsor, Katherine
    Rhieu, Steve Y.
    Geiser, Gerlie
    Banerjee, Anamitro
    Chen, Xiaohong
    Turcu, Francisca Reyes
    Chatterjee, Deb K.
    Pathak, Anand
    Seidman, Jeffrey
    Ghosh, Soma
    Philip, Reena
    Goldberg, Kirsten B.
    Kluetz, Paul G.
    Tang, Shenghui
    Amiri-Kordestani, Laleh
    Theoret, Marc R.
    Pazdur, Richard
    Beaver, Julia A.
    CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1842 - 1849
  • [49] Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer
    Hoste, Griet
    Slembrouck, Laurence
    Jongen, Lynn
    Punie, Kevin
    Matton, Tom
    Vander Borght, Sara
    Vanden Bempt, Isabelle
    Menten, Johan
    Wildiers, Hans
    Floris, Giuseppe
    Arteaga, Carlos
    Neven, Patrick
    CLINICAL DRUG INVESTIGATION, 2018, 38 (11) : 1071 - 1075
  • [50] Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer
    Griet Hoste
    Laurence Slembrouck
    Lynn Jongen
    Kevin Punie
    Tom Matton
    Sara Vander Borght
    Isabelle Vanden Bempt
    Johan Menten
    Hans Wildiers
    Giuseppe Floris
    Carlos Arteaga
    Patrick Neven
    Clinical Drug Investigation, 2018, 38 : 1071 - 1075
12345